Asad Javed, MD
Hematology & Oncology · Orland Park, ILNPI 1427339928
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,625 of the $2,503 with a category attached, or 64.9%. Immunocore Limited accounts for 90.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $1,349 and has fallen 90.2% since, to $132 in 2025. That places this record below the midpoint for hematology & oncology clinicians in IL, where the typical reported total is $2,365.
Across 9 payments — averaging $278.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immunocore Limited$2K
- Delcath Systems$132
- Boehringer Ingelheim$95
Across 5 payments — averaging $35,886 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$177K
- Iovance Biotherapeutics, Inc.$2K
What the payments were for
- Consulting fees$1,62565%
- Speaking & faculty fees$65026%
- Food & beverage$2289%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immunocore Limited | 4 | $2,275 |
| Delcath Systems | 1 | $132 |
| Boehringer Ingelheim | 4 | $95 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KIMMTRAK$2,275
- Hepzato Kit$132
How this compares
$2,503 in reported general payments places this provider in the 50th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BraftoviEncorafenib | 32 | $372,525 |
| MektoviBinimetinib | 32 | $278,561 |
| EliquisApixaban | 18 | $11,727 |
| Enoxaparin Sodium | 15 | $3,765 |
| Hydrocortisone | 38 | $794 |
| Oxycodone Hcl | 14 | $129 |
| Prednisone | 33 | $112 |
| Levothyroxine Sodium | 24 | $98 |
| Pantoprazole Sodium | 11 | $45 |
| Hydrochlorothiazide | 13 | $43 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Orland Park
- Mohamad Khair KhasawnehMaywood$998K
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- John BerryBerwyn$687K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Tulio RodriguezZion$337K
- Chih-Yi LiaoChicago$317K
- Gary KayElk Grove Village$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.